This bill amends Title XVIII of the Social Security Act to change Part D benefit design and utilization management for a narrowly defined set of non‑opioid drugs indicated to treat postoperative or other acute pain. It requires plans to waive the Part D deductible for those drugs, place them on the lowest cost‑sharing tier, and prohibits step therapy that forces use of opioids first as well as any prior authorization for those products.
The measure targets uptake of FDA‑approved, non‑opioid acute‑pain therapies that have no U.S. therapeutically equivalent alternative and whose monthly wholesale acquisition cost falls below the Secretary’s specialty‑tier threshold. For providers, manufacturers, plans, and CMS, the law reorders formulary incentives and removes common utilization controls for a discrete drug class — with fiscal, administrative, and clinical implications for opioid‑sparing policy in Medicare.
At a Glance
What It Does
The bill adds a new subsection that (1) excludes qualifying non‑opioid acute‑pain drugs from the Part D deductible and requires plans to place them on the lowest cost‑sharing tier, and (2) forbids Part D prescription drug plans and MA‑PD plans from applying step therapy that mandates an opioid first or any prior authorization for those drugs. It also amends low‑income subsidy rules to ensure the same treatment for subsidy‑eligible enrollees.
Who It Affects
Directly affects Medicare Part D prescription drug plans and Medicare Advantage plans with drug benefits (MA‑PDs), manufacturers of non‑opioid acute‑pain products, pharmacists dispensing those drugs, and Medicare beneficiaries with postoperative or acute pain — including low‑income subsidy recipients.
Why It Matters
The bill uses benefit design and utilization‑management limits to promote a specific category of opioid‑sparing drugs, potentially increasing their uptake while constraining plans’ formulary tools. That combination reshapes incentives for prescribing, contracting, and drug pricing within Part D and could set a precedent for targeted, class‑based mandates in federal drug benefits.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends two core parts of the Part D statutory framework. It inserts a new paragraph into the Part D benefit rules that creates a special treatment for a defined group of drugs: those with an FDA label for postoperative or other acute pain, that are not opioid receptor agonists, that have no therapeutically equivalent product marketed in the U.S., and whose monthly wholesale acquisition cost (WAC) stays below the Secretary’s specialty‑tier threshold.
For such drugs the Part D deductible does not apply and plans must assign them to the lowest cost‑sharing tier available when calculating coinsurance or other cost sharing.
To make that protection apply to low‑income beneficiaries, the bill adds a conforming paragraph to the Part D rules governing low‑income subsidy treatment so those enrollees also face no deductible and the same lowest‑tier placement for qualifying drugs. The statute ties the price cap to the WAC for a monthly supply and explicitly leaves the specialty‑tier threshold as a figure the Secretary will determine from time to time, which means the administrative definition will change with CMS policy rather than being a fixed dollar amount in statute.On utilization management, the bill amends the Part D utilization‑management prohibition provisions to bar plans from imposing step therapy that would require a patient to take an opioid before a qualifying non‑opioid drug, and to bar any prior authorization requirement for those drugs.
The bill also performs the mechanical task of redesignating an existing paragraph in the utilization‑management statute to accommodate this new prohibition.Operationally, the law forces plans and CMS to identify qualifying products, code them appropriately on formularies, and adjust benefit designs and point‑of‑sale systems so deductible waivers and tier placement operate correctly for the affected fills. Because the qualifying test depends on FDA labeling, therapeutic equivalence listings, and a price test tied to the Secretary’s threshold, implementation will require coordination between CMS, plan sponsors, PBMs, and drug manufacturers to determine which drugs meet the statutory criteria and when that status changes.
The Five Things You Need to Know
Effective date: the bill’s new rules apply to plan years beginning on or after January 1, 2026.
Statutory definition: a “qualifying non‑opioid pain management drug” must have an FDA‑approved label for postoperative or other acute pain, not act on opioid receptors, and have no therapeutically equivalent product listed in the FDA’s Orange Book sold in the U.S.
Price cap mechanic: eligibility also requires that the wholesale acquisition cost for a monthly supply does not exceed the Secretary’s periodically determined monthly specialty‑tier cost threshold.
Benefit change plus subsidy parity: the statute both waives the Part D deductible for qualifying products and amends the low‑income subsidy provisions so subsidy‑eligible beneficiaries receive the same deductible waiver and lowest‑tier placement.
Utilization limits: the bill expressly prohibits Part D prescription drug plans and MA‑PD plans from using step therapy that forces opioid use first and from imposing any prior authorization for qualifying drugs (it also redesignates an existing paragraph to add this prohibition).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the bill’s short titles: the "Alternatives to Prevent Addiction In the Nation Act" and the "Alternatives to PAIN Act." This is purely nominal but is the statutory anchor used in rulemaking citations and cross‑references.
Cost‑sharing and qualifying‑drug definition
Adds paragraph (10) to 1860D–2(b) creating the new treatment for qualifying non‑opioid drugs. Paragraph (10)(A) requires plans, beginning in 2026 plan years, to waive the Part D deductible for covered drugs that meet the statute’s definition and to place those drugs on the lowest cost‑sharing tier for purposes of calculating coinsurance or other cost sharing. Paragraph (10)(B) sets a four‑part eligibility test (FDA acute‑pain label, non‑opioid receptor mechanism, absence of a U.S. therapeutically equivalent product in the Orange Book, and a WAC price test tied to the Secretary’s specialty threshold). Practically, this compels sponsors to reconfigure formulary tier mappings and benefit calculators to treat qualifying drugs differently at point of sale.
Low‑income subsidy parity
Adds paragraph (7) to the Part D low‑income subsidy section so subsidy recipients receive the same deductible waiver and lowest‑tier placement for qualifying drugs. This prevents a subsidy‑eligible enrollee from facing a deductible or higher tier for drugs the statute otherwise protects. Sponsors will need to ensure their LIS billing logic mirrors the new Part D rules to avoid incorrect cost sharing for eligible fills.
Ban on opioid‑first step therapy and prior authorization
Amends the utilization‑management prohibition section by adding paragraph (8), which bars step therapy protocols that require an opioid before coverage of a qualifying non‑opioid drug and bars any prior authorization requirement for those drugs. The bill also redesignates the existing paragraph (6) as (7) to accommodate the insertion. Practically, plans must remove opioid‑first edits and prior‑auth rules for qualifying products and adjust appeals and exceptions procedures accordingly.
Secretary and plan administrative responsibilities
Although the bill does not create a new CMS rulemaking timeline, it leaves several operational determinations to the Secretary — notably the monthly specialty‑tier cost threshold and how CMS will identify qualifying drugs when products gain or lose Orange Book equivalence or when labels change. That means CMS must build criteria and operational guidance; plans and PBMs must update formulary files, point‑of‑sale systems, and communication protocols with pharmacies and manufacturers to ensure correct pricing and utilization‑management behavior at the pharmacy counter.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries with postoperative or acute pain — they face lower out‑of‑pocket costs and fewer administrative hurdles for qualifying non‑opioid drugs, increasing access at the pharmacy counter.
- Low‑income subsidy (LIS) beneficiaries — the conforming amendment extends deductible waivers and lowest‑tier placement to LIS recipients, eliminating a gap between general Part D treatment and subsidy rules.
- Manufacturers of qualifying non‑opioid drugs — they gain a formulary advantage: favorable tier placement and no prior authorization or step‑therapy barriers, which can increase uptake and market share for qualifying products.
- Clinicians and surgical centers aiming to reduce opioid exposure — fewer prior‑auth and step‑therapy constraints can make it easier to prescribe opioid‑sparing regimens immediately after surgery.
- Public health advocates focusing on opioid‑sparing strategies — the policy uses benefit design to encourage alternatives to opioids, aligning financial incentives with clinical goals.
Who Bears the Cost
- Part D plan sponsors and MA‑PD plans — they must absorb lower patient cost sharing and the loss of prior‑authorization and step‑therapy tools for qualifying drugs, which can increase plan drug spending or shift costs elsewhere in the benefit design.
- PBMs, pharmacists, and plan administrators — they face implementation costs: identifying qualifying products, reprogramming point‑of‑sale systems, updating formulary and tier files, and revising exception and appeals workflows.
- Centers for Medicare & Medicaid Services — CMS must develop operational guidance, set and update the specialty‑tier threshold, and adjudicate classification disputes without new appropriations, adding administrative burden.
- Medicare program finances or premiums — if plan liabilities rise materially, plans may seek higher bids or premium adjustments; that fiscal effect is an indirect cost borne by beneficiaries and taxpayers via premiums or plan payments.
Key Issues
The Core Tension
The bill confronts a central trade‑off: improve patient access to specific non‑opioid acute‑pain therapies by removing cost and administrative barriers, or preserve plan formulary and utilization tools to control spending and clinical use. Prioritizing access for one drug class narrows plan discretion and can raise costs or create gaming opportunities; preserving plan control risks perpetuating barriers that deter opioid‑sparing prescribing. There is no single policy that simultaneously guarantees broad access, tight clinical targeting, and minimal fiscal impact.
The statute’s eligibility test creates multiple operational and policy frictions. Tying qualification to the absence of a therapeutically equivalent product in the FDA’s Orange Book rewards drugs that are unique in markets where generic competition is absent; it does not directly account for comparative effectiveness or cost‑effectiveness versus multi‑agent regimens.
Manufacturers could exploit the ‘‘no equivalent’’ criterion by pursuing label language or product differentiation that narrows competition and preserves the statutory advantage. Because the price test relies on WAC relative to an administratively determined specialty‑tier threshold, eligibility can change as the Secretary adjusts that threshold, producing uncertainty for plans, prescribers, and patients.
The prohibition on prior authorization and opioid‑first step therapy reduces administrative barriers but also removes utilization controls that plans use to manage inappropriate use and costs. Without new clinical guardrails, plans cannot require stepped approaches that reserve the protected drugs for situations where they are clinically indicated; that could increase off‑label or broader use in settings where evidence is weaker.
Finally, CMS and plans will need to revise operational systems fast to meet a January 1, 2026 effective date; the bill does not specify dispute resolution, transitional coding, or appeals pathways for contested qualifying‑drug designations, leaving important implementation questions unresolved.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.